At NashBio, we make complex healthcare data easy to use. From idea to execution, we leverage real-world clinical, genomic and imaging data to advance the discovery and development of new therapeutics and diagnostics.
Smarter Data is in Our DNA
At NashBio, we make complex healthcare data easy to use. From idea to execution, we leverage real-world clinical, genomic and imaging data to advance the discovery and development of new therapeutics and diagnostics.
Modern healthcare systems produce endless amounts of data, but finding the right data to enhance your organization’s research and development activity can be a big challenge.
Our approach focuses on your use case: tailoring a multimodal dataset to your unique specifications to achieve an optimal return on your clinical, operational and financial investment.
Modern healthcare systems produce endless amounts of data, but finding the right data to enhance your organization’s research and development activity can be a big challenge.
Our approach focuses on your use case: tailoring a multimodal dataset to your unique specifications to achieve an optimal return on your clinical, operational and financial investment.
Advance novel discoveries and products with real-world data enabled for research and discovery.
Multimodal & Multi-Omic Data
Seamlessly integrate diverse data types to unlock the full spectrum of biological information.
Enriched Phenotypes
Identify cohorts with a breadth of disease-specific features and years of longitudinal clinically relevant data.
Demographically Diverse
Select patients from a diverse population relative to age, disease and other demographics.
Industry Experts
Collaborate with our scientific and clinical experts to find the right data for your use case.
Strategic Partners
Accelerate speed to market with our flexible, customer-centric approach and proven commercial track record.
Our clients and partners include many of the world’s leading health care organisations.
Our Products
Our offerings leverage the richest and largest de-identified EMR and linked bio-specimen repository in the world, BioVU®.
Clinical Data
Smarter data that enables research and discovery
When patients visit Vanderbilt University Medical Center (VUMC), their clinical encounters are documented in VUMC’s electronic health record (EHR). NashBio’s Clinical Data is a synthetic derivative of this EHR, created to enable research and discovery, and is the backbone of our offerings.
Precision medicine, an approach to patient care that is tailored to the individual, is an attainable goal. A key component of precision medicine is a patient’s genes and how their genes influence their risk of disease & progression and their response to treatment. NashBio’s data covers both the phenotypic and the genotypic patient data, enabling the interrogation of these interactions.
Smarter data that enables better insights into disease
Biological samples offer insight into the molecular processes at play in our cells and deepen our understanding of human disease. BioVU® is a collection of biosamples that are linked to patients’ electronic health records and scrubbed of all personal identifiers. Assays may be performed on these biosamples to generate new omic data linked to each patient’s phenome.
Images are a powerful tool for diagnostic and interventional purposes. By nature, medical imaging is non to minimally invasive, and consequently is a preferred procedure when monitoring and when repeat acquisition are required. When these images are linked to a patient’s EHR, they enable the development of deep, longitudinal, multi-modal phenotypes.
Waveform data are a key component of many clinical decision workflows
Care teams rely on real-time monitoring from electrocardiograms (ECGs), mechanical ventilators, electroencephalograms (EEGs) and other high frequency data streams to quickly detect changes in a patient’s health and guide decision making for safe and effective treatment plans.
Smarter data that enables deeper analysis and discovery
Large-scale association analyses are commonly performed to link phenotypic and genomic datasets. Study findings may elucidate new targets for drug discovery, expand existing drug labels or new populations that would benefit from a therapeutic. NashBio’s 90,000-subject MEGAEX + linked de-identified electronic health records dataset serves as the substrate for our association studies.
When patients visit Vanderbilt University Medical Center (VUMC), their clinical encounters are documented in VUMC’s electronic health record (EHR). NashBio’s Clinical Data is a synthetic derivative of this EHR, created to enable research and discovery, and is the backbone of our offerings.
Precision medicine, an approach to patient care that is tailored to the individual, is an attainable goal. A key component of precision medicine is a patient’s genes and how their genes influence their risk of disease & progression and their response to treatment. NashBio’s data covers both the phenotypic and the genotypic patient data, enabling the interrogation of these interactions.
Smarter data that enables better insights into disease
Biological samples offer insight into the molecular processes at play in our cells and deepen our understanding of human disease. BioVU® is a collection of biosamples that are linked to patients’ electronic health records and scrubbed of all personal identifiers. Assays may be performed on these biosamples to generate new omic data linked to each patient’s phenome.
Images are a powerful tool for diagnostic and interventional purposes. By nature, medical imaging is non to minimally invasive, and consequently is a preferred procedure when monitoring and when repeat acquisition are required. When these images are linked to a patient’s EHR, they enable the development of deep, longitudinal, multi-modal phenotypes.
Waveform data are a key component of many clinical decision workflows
Care teams rely on real-time monitoring from electrocardiograms (ECGs), mechanical ventilators, electroencephalograms (EEGs) and other high frequency data streams to quickly detect changes in a patient’s health and guide decision making for safe and effective treatment plans.
Smarter data that enables deeper analysis and discovery
Large-scale association analyses are commonly performed to link phenotypic and genomic datasets. Study findings may elucidate new targets for drug discovery, expand existing drug labels or new populations that would benefit from a therapeutic. NashBio’s 90,000-subject MEGAEX + linked de-identified electronic health records dataset serves as the substrate for our association studies.
Our offerings leverage the richest and largest de-identified EMR and linked bio-specimen repository in the world, BioVU®. We utilize our diverse product offerings to create custom solutions curated to drive results for our clients.
Our offerings leverage the richest and largest de-identified EMR and linked bio-specimen repository in the world, BioVU®. We utilize our diverse product offerings to create custom solutions curated to drive results for our clients.
Real World Data Cohort Design
Nashville Biosciences recently worked with a clinical stage biotech to develop a synthetic control arm for its active single-arm clinical trial in a rare but…
Acute pancreatitis has become increasingly prevalent across the world, affecting nearly 85,000 individuals annually. Patients with acute pancreatitis experience…
Nashville Biosciences recently worked with Pfizer’s Target Sciences and Technologies group to explore genetic targets for treating a serious metabolic disease with greatly increasing…
Nashville Biosciences recently worked with a clinical stage biotech to develop a synthetic control arm for its active single-arm clinical trial in a rare but…
Acute pancreatitis has become increasingly prevalent across the world, affecting nearly 85,000 individuals annually. Patients with acute pancreatitis experience…
Nashville Biosciences recently worked with Pfizer’s Target Sciences and Technologies group to explore genetic targets for treating a serious metabolic disease with greatly increasing…
NashBio was created to make unique, complex data from the patient’s healthcare journey easy to use. We provide curated datasets within the context of each individual patient’s journey, so you understand the full picture of each patient’s data and are able to put the data to work for your unique goals.
NashBio was created to make unique, complex data from the patient’s healthcare journey easy to use. We provide curated datasets within the context of each individual patient’s journey, so you understand the full picture of each patient’s data and are able to put the data to work for your unique goals.
AGD aims to accelerate the development of novel therapeutics through the use of large-scale genomics and the creation of a preeminent real-world genomic resource.
AGD aims to accelerate the development of novel therapeutics through the use of large-scale genomics and the creation of a preeminent real-world genomic resource.
Genomics is one of the fastest developing research areas in the world today. Due to rapid advancements, in-depth genetic analysis has become essential in R&D and clinical practice.
With drug development costs forecast to double every nine years, we need more than ever to improve R&D productivity and uncover new ways to diagnose and care for diseases more efficiently. In order to increase the speed-to-market for life sciences companies, it’s imperative that we fully recognize and capture the potential of human genetics in drug and diagnostics R&D.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy